You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.
In PNAS this week: role for RTP4 gene in severe malaria, other infections; CRISPR-based approach to alter gene expression; and more.
In Nucleic Acids Research this week: statistical tool to track temporal gene expression, effects of transcription factor variants on bacterial regulatory gene networks, and more.
In PNAS this week: genomic analysis of the venomous Hispaniolan solenodon, Epstein-Barr virus amplification in replication compartments, and more.
In Nature this week: catalog of changes associated with gene knockouts in yeast, simultaneous profiling of three-dimensional genome structure and DNA methylation in single cells, and more.
In Genome Research this week: PeCanPIE platform for finding, annotating, and ranking pathogenic variants; commensal Escherichia coli analysis; and more.
Researchers warn that there are finite ancient samples for genetic analysis and argue that policies should be in place to ensure they are studied responsibly.
In PLOS this week: variations in the way synonymous DNA codons are used in yeast, links between germline TP53 mutations and recurrent somatic mutations in bladder cancer, and more.
An ABRF working group compared three dyes for Sanger sequencing to find that, even with their differences in price, they all performed similarly.
With metagenomics, genomics, and other analyses, researchers saw a potential antifungal compound called cyphomycin produced by Streptomyces in an ant in Brazil.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.